 phase recombinant human interferon-alpha human lymphoblastoid interferon-alpha concomitant zidovudine patients AIDS-related Kaposi sarcoma safety maximum dose preliminary efficacy concomitant interferon-alpha zidovudine therapy AIDS-related Kaposi sarcoma KS patients biopsy-proven KS human immunodeficiency virus type HIV infection phase Interferon-alpha dose mu day zidovudine mg weeks maintenance period major toxicities neutropenia hepatotoxicity Neutropenia dose mg zidovudine/day dose interferon-alpha mu/day Hepatotoxicity dose mu interferon mg zidovudine/day Cumulative dose-related anemia neutropenia long-term follow-up maximum tolerated doses combination mu interferon-alpha mg zidovudine Variable changes lymphocytes first weeks therapy doses combination increases median lymphocyte numbers HIV antigenemic patients progressive antigen suppression doses combination overall antitumor response rate Tumor regression survival benefits pretreatment cell count equal conclusion intermediate doses interferon-alpha doses zidovudine disease improvement survival benefits